StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) stock

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Karyopharm Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Karyopharm Therapeutics's total assets was $111.32M at Jun 30, 2026. For fiscal 2025 it was $108.42M, down 34.1% from the year before. Over ten years it grew -6.6% a year on average. The highest annual figure on record is $358.17M in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$108.42M-34.1%
FY2024Dec 31, 2024$164.42M-31.6%
FY2023Dec 31, 2023$240.44M-32.9%
FY2022Dec 31, 2022$358.17M+17.3%
FY2021Dec 31, 2021$305.31M-2.5%
FY2020Dec 31, 2020$313.05M+6.1%
FY2019Dec 31, 2019$294.96M-13.5%
FY2018Dec 31, 2018$341.19M+89.2%
FY2017Dec 31, 2017$180.29M-0.1%
FY2016Dec 31, 2016$180.39M-16.3%
FY2015Dec 31, 2015$215.44M-2.2%
FY2014Dec 31, 2014$220.34M+39.3%
FY2013Dec 31, 2013$158.23M+11969.1%
FY2012Dec 31, 2012$1.31M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$111.32M+6.1%
Q1 FY2026Mar 31, 2026$131.42M+2.9%
Q4 FY2025Dec 31, 2025$108.42M-34.1%
Q3 FY2025Sep 30, 2025$96.23M-49.2%
Q2 FY2025Jun 30, 2025$104.88M-51.0%
Q1 FY2025Mar 31, 2025$127.71M-37.5%
Q4 FY2024Dec 31, 2024$164.42M-31.6%
Q3 FY2024Sep 30, 2024$189.48M-29.8%
Q2 FY2024Jun 30, 2024$213.98M-28.2%
Q1 FY2024Mar 31, 2024$204.46M-37.2%
Q4 FY2023Dec 31, 2023$240.44M-32.9%
Q3 FY2023Sep 30, 2023$269.96M+16.7%
Q2 FY2023Jun 30, 2023$297.83M+16.1%
Q1 FY2023Mar 31, 2023$325.80M+10.8%
Q4 FY2022Dec 31, 2022$358.17M+17.3%
Q3 FY2022Sep 30, 2022$231.24M-9.0%
Q2 FY2022Jun 30, 2022$256.48M-10.5%
Q1 FY2022Mar 31, 2022$294.03M+7.0%
Q4 FY2021Dec 31, 2021$305.31M-2.5%
Q3 FY2021Sep 30, 2021$254.09M-24.7%
Q2 FY2021Jun 30, 2021$286.57M-24.6%
Q1 FY2021Mar 31, 2021$274.91M-33.9%
Q4 FY2020Dec 31, 2020$313.05M+6.1%
Q3 FY2020Sep 30, 2020$337.59M+13.4%
Q2 FY2020Jun 30, 2020$380.01M+59.6%
Q1 FY2020Mar 31, 2020$416.14M+44.9%
Q4 FY2019Dec 31, 2019$294.96M-13.5%
Q3 FY2019Sep 30, 2019$297.75M+35.3%
Q2 FY2019Jun 30, 2019$238.10M-7.2%
Q1 FY2019Mar 31, 2019$287.21M+96.2%
Q4 FY2018Dec 31, 2018$341.19M+89.2%
Q3 FY2018Sep 30, 2018$219.99M+34.3%
Q2 FY2018Jun 30, 2018$256.59M+38.1%
Q1 FY2018Mar 31, 2018$146.37M-5.8%
Q4 FY2017Dec 31, 2017$180.29M-0.1%
Q3 FY2017Sep 30, 2017$163.77M-10.8%
Q2 FY2017Jun 30, 2017$185.75M–
Q1 FY2017Mar 31, 2017$155.44M–
Q4 FY2016Dec 31, 2016$180.39M–
Q3 FY2016Sep 30, 2016$183.62M–

More Karyopharm Therapeutics figures

See a number that looks wrong?